Home

Merck Kgaa ADR (MKKGY)

25.41
-1.36 (-5.08%)
OP · Last Trade: Apr 5th, 2:13 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close26.77
Open26.11
Bid-
Ask-
Day's Range25.41 - 26.18
52 Week Range25.33 - 39.17
Volume105,962
Market Cap-
PE Ratio (TTM)-
EPS (TTM)-
Dividend & YieldN/A (N/A)
1 Month Average Volume113,199

Chart

News & Press Releases

WeRide, CRISPR And GeneDx Are Among Top 10 Mid-Cap Gainers Last Week (Feb 10-Feb 14): Are The Others In Your Portfolio?benzinga.com
Top performing mid-cap stocks last week: WRD (+97.62%), GDS (+43.45%), SWTX (+42.58%), RXRX (+40.59%), SOC (+39.09%), WGS (+28.23%), VNET (+28.22%), NSP (+25.99%), CRSP (+25.21%), AXSM (+24.01%)
Via Benzinga · February 16, 2025
Germany's Merck In Talks To Buy Cancer Drug Maker SpringWorks Therapeuticsbenzinga.com
Merck KGaA is in advanced talks to acquire SpringWorks, whose portfolio could bolster Merck's oncology business amid patent expirations and competition.
Via Benzinga · February 11, 2025
GSK To Buy US-Based Stomach Cancer Drug Developer For Over $1 Billionbenzinga.com
GSK's $1 billion acquisition of IDRx includes IDRX-42, a precision therapy for GIST. Phase 1/1b trial shows 53% ORR in early treatment stages.
Via Benzinga · January 13, 2025
Pfizer Clears Required Regulatory Hurdles To Complete $43B Seagen Acquisitionbenzinga.com
Pfizer Inc (NYSE: PFE) 
Via Benzinga · December 12, 2023
Germany's Merck To Launch Semiconductor Base In Chinabenzinga.com
Via Benzinga · May 31, 2022
Merck Germany's Two Pivotal Trials Flunk In Multiple Sclerosisbenzinga.com
Merck KGaA (OTC: MKGAF) (OTC: 
Via Benzinga · December 6, 2023
Life Sciences Player Repligen's Strategic European Acquisition - What It Means for Investorsbenzinga.com
Repligen Corporation (NASDAQ: RGEN) agreed to acquire Sweden-based privately-held Metenova. 
Via Benzinga · September 26, 2023
Merck Germany Reports 5% Decline In Q2 Sales, Expects More Decline In 2023benzinga.com
Merck KGa Germany (OTC: MKGAF) (OTC: MKKGY) reported 
Via Benzinga · August 3, 2023
Novo Nordisk's Obesity Drug Saxenda Not Included In WHO's Essential Drug Listbenzinga.com
The World Health Organization (WHO) published the new editions of the Model Lists of Essential Medicines (EML) and Essen
Via Benzinga · July 26, 2023
Abcam Downgrade: Analyst Trims Expectations Amid Activist Investor Engagement and Potential Bid Anticipationbenzinga.com
RBC Capital Markets has downgraded Abcam PLC (NASDAQ: ABCM) from Outperform to Sector Perform with a price target of $22, 
Via Benzinga · June 20, 2023
Analyst Says Nektar Therapeutics' Rezpeg Prioritization Likely to Spark Investor Questionsbenzinga.com
Via Benzinga · April 18, 2023
FDA Issues Partial Clinical Hold On Merck Germany's Multiple Sclerosis Studybenzinga.com
Via Benzinga · April 12, 2023
Merck Germany Regains Exclusive Global Rights To Cancer Drug From Pfizerbenzinga.com
Via Benzinga · March 27, 2023
Incyte Would Now Compete With Merck, Pfizer As Its Skin Cancer Treatment Scores FDA Accelerated Approvalbenzinga.com
Via Benzinga · March 23, 2023
With Upcoming Ovarian Cancer Data, Analyst Sees 100% Upside For Mersana Therapeuticsbenzinga.com
Via Benzinga · January 20, 2023
PDS Biotech, Merck Germany Enter Licensing Pact For Investigational Cancer Treatmentbenzinga.com
Via Benzinga · January 3, 2023
Mersana Inks Cancer Therapy Development Deal With Merck Germanybenzinga.com
Via Benzinga · December 23, 2022
SpaceX Starlink's New In-Flight Connectivity Service, Amazon's NY Workers Reject Union, Celsius Network Faces Several Federal Investigations: Top Stories Wednesday, Oct. 19benzinga.com
Reuters US Lawmakers Plan Hearing On Kroger, Albertsons' $25B Merger
Via Benzinga · October 19, 2022
Germany's Merck Slapped With Formal French Investigation Related To Its Thyroid Drugbenzinga.com
The French court is reportedly investigating Germany-based Merck KGaA (OTC: MKKGY), saying the company provided misleading information regarding its thyroid drug product Levothyrox.
Via Benzinga · October 19, 2022
PDS Biotech Highlights Expanded Data From PDS0101 Triple Combination Trial In HPV-Positive Cancersbenzinga.com
Via Benzinga · October 11, 2022
TSM Looks To Hire Over 8,000 People In 2022benzinga.com
Taiwan’s top two chipmakers plan to hire over 10,000 engineers in 2022 to bolster their aggressive expansion plans and maintain their technological edge, Financial...
Via Benzinga · January 24, 2022
Despite Palantir’s Impressive Deals, Its Losses and Valuation Make It Unappetizinginvestorplace.com
Amid continued questions about the profitability and the competitive advantages of Palantir in a crowded field, PLTR stock remains a sell.
Via InvestorPlace · January 21, 2022
The Daily Biotech Pulse: Pfizer Strikes $5.29B COVID Pill Supply Deal With US, Roche's Spark Therapeutics Reports Positive Gene Therapy Readout, EDAP Earningsbenzinga.com
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Roche's Spark Subsidiary Reports Positive Phase 1/2 Data For Hemophilia...
Via Benzinga · November 18, 2021
GlaxoSmithKline, Merck KGaA End $4B Cancer Drug Pactbenzinga.com
Merck KGaA (OTC: MKGAF) and GlaxoSmithKline Plc (NASDAQ: GSK) have ended their $4 billion collaboration on cancer treatment, bintrafusp alfa. Merck said...
Via Benzinga · September 30, 2021
Nektar, Merck Germany, Pfizer Join Forces For Mid-Stage Bladder Cancer Studybenzinga.com
Nektar Therapeutics Inc (NASDAQ: NKTR) has entered into a new oncology clinical collaboration with Merck KGaA (OTC: MKGAF) and Pfizer Inc (NYSE...
Via Benzinga · September 21, 2021